In the following promotional video produced by Mevion, the company spoke to representatives from the organizations utilizing their equipment to help potential customers understand the company's value proposition:
The Ackerman Cancer Center is currently in the process of adding a second Mevion system to its facility. Its MEVION S250i, with HYPERSCAN pencil beam capabilities, is expected to be fully installed next year.
Last summer, when HCB News asked Jachinowski what the global MEVION S250 install base might look like five years from now, he estimated somewhere in the ballpark of 40 facilities.
About a month later, the proton therapy OEM announced an investment agreement with HOPU Investments, YuanMing Capital, and participated in by other Chinese investors and U.S. investors, where up to $200 million would be invested in Mevion to accelerate its worldwide expansion. Back to HCB News
